Serum amyloid beta protein in young and elderly depression: a pilot study

Area of Science:

• Neuroscience
• Biochemistry
• Gerontology

Background:

• Major depressive disorder (MDD) is a potential risk factor for Alzheimer's disease (AD).
• Plasma amyloid beta (Abeta) levels, specifically the Abeta42/40 ratio, are implicated in AD risk.
• Previous studies on Abeta levels in depressed elderly individuals yielded inconsistent results, with no data on younger populations.

Purpose of the Study:

• To investigate serum Abeta40, Abeta42 levels, and the Abeta40/42 ratio in patients with MDD compared to healthy controls.
• To analyze these biomarkers in distinct age groups (younger and elderly) to identify age-specific differences.

Main Methods:

• Serum samples from 60 MDD patients and 60 healthy controls were analyzed using enzyme-linked immunosorbent assay (ELISA).
• Measurements included Abeta40 and Abeta42 levels, and the calculated Abeta40/42 ratio.
• Data were stratified and analyzed for two age groups: <60 years (young) and >=60 years (elderly).

Main Results:

• Serum Abeta40 levels were significantly higher in young MDD patients versus young controls.
• No significant difference in serum Abeta42 levels was observed between MDD patients and controls in either age group.
• The serum Abeta40/42 ratio was significantly elevated in MDD patients compared to controls across both young and elderly groups.

Conclusions:

• An elevated serum Abeta40/42 ratio is a potential biomarker for MDD, observed in both younger and older adults.
• This elevation suggests that early-stage amyloid deposition may occur in young individuals with MDD.
• The findings support a potential link between depression and the early pathological changes associated with Alzheimer's disease.